Zensar Technologies Completes Filings for US Subsidiary Mergers with Zensar Technologies Inc.
Zensar Technologies Limited has confirmed the completion of requisite local filings in connection with the mergers of two US-based subsidiaries into its subsidiary, Zensar Technologies Inc., USA. The company provided updates regarding both Bridgeview Life Sciences LLC and M3BI LLC, which are merging with Zensar Technologies Inc.The Board of Directors of Zensar had previously accorded in-principle approval for the merger of Bridgeview Life Sciences LLC and M3BI LLC with Zensar Technologies Inc., a wholly owned subsidiary of the company. All necessary filings related to the merger of Bridgeview Life Sciences LLC with Zensar Technologies Inc. were completed previously.
Regarding M3BI LLC, the necessary filings with relevant local authorities and state agencies were completed on August 13, 2026. Consequently, the merger of M3BI LLC with Zensar Technologies Inc. is scheduled to become effective from September 1, 2026.
With the successful completion of all requisite filings concerning both Bridgeview Life Sciences LLC and M3BI LLC, the company has confirmed that these mergers are now complete in terms of local authority and state agency requirements. The company noted that certain post-merger and consequential filings remain under process and are expected to be completed in due course.
ZENSARTECH Stock Price Movement
As of 1:41 PM, shares of Zensar Technologies Limited are slipping down in live trading, shedding ₹6.25 or 1.25% and currently finding a price of ₹492.40. The stock posted a total traded volume of 326,531 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.